Poly(ethyleneglycol) 500 dimethylether as novel solvent for injectable in situ forming depots

Pharmaceutical Research

Volumn 26, Issue 12, 2009, Pages 2568-2577

  Schoenhammer, Karin ^a,b   Petersen, Holger ^a   Guethlein, Frank ^a   Goepferich, Achim ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Degradation; In situ forming depot; Poly(D,L lactide co glycolide); Stability

Indexed keywords

1 METHYL 2 PYRROLIDINONE; MACROGOL 500 DIMETHYLETHER; MACROGOL 600; MACROGOL DERIVATIVE; POLYGLACTIN; SOLVENT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION COEFFICIENT; DRUG DEGRADATION; DRUG FORMULATION; DRUG STABILITY; FEMALE; FLOW KINETICS; HEMOLYSIS; HUMAN; HUMAN TISSUE; MALE; PHASE SEPARATION; PRECIPITATION; PRIORITY JOURNAL; VISCOSITY;

BLOOD DONORS; DRUG STABILITY; ETHERS; FEMALE; HEMOLYSIS; HUMANS; MALE; POLYETHYLENE GLYCOLS; PYRROLIDINONES; SOLVENTS; VISCOSITY;

EID: 70449134629     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-009-9969-0     Document Type: Article

References (22)

1. HB Ravivarapu KL Moyer RL Dunn 2000 Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide Int J Pharm 194 181 191 10.1016/S0378-5173(99)00371-3 1:CAS:528:DC%2BD3cXht1eqtrk%3D 10692642 (Pubitemid 30110680)
2. International congress on harmonisation. Guideline: Impurities: Guideline for residual solvents Q3C(R3).
3. MF Powell T Nguyen L Baloian 1998 Compendium of excipients for parenteral formulations PDA J Pharm Sci Technol 52 238 311 1:CAS:528:DyaK1MXmvFKh 9846074
4. Kempe S, Metz H, Pereira PGC, Maeder K. Non-invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopy. Eur J Pharm Biopharm. 2009; doi: 10.1016/j.ejpb.2009.06. 008. accepted manuscript.
5. Shively ML, Coonts BA, Renner WD, Southard JL, Bennett AT. Physico-chemical characterization of a polymeric injectable implant delivery system. J Control Release. 1995;33:237-243.
6. K Schoenhammer H Petersen F Guethlein A Goepferich 2008 Injectable in- situ forming depot systems: PEG-DAE as a novel solvent for improved storage stability Int J Pharm 10.1016/j.ijpharm.2008.12.019 19135512 accepted manuscript
7. JM Ginés MJ Arias AM Rabasco C Novak A Ruiz-Conde PJ Sanchez-Soto 1996 Thermal characterization of polyethylene glycols applied in the pharmaceutical technology using differential scanning calorimetry and hot stage microscopy J Therm Anal Calorim 46 291 304 10.1007/BF01979969
8. S Kempe H Metz K Maeder 2008 Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process J Control Release 130 220 225 10.1016/j.jconrel.2008.06.006 1:CAS:528:DC%2BD1cXhtFSqsb%2FM 18611421
9. R Astaneh M Erfan H Moghimi H Mobedi 2009 Pharmaceutics, preformulation and drug delivery changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior J Pharm Sci 98 135 145 10.1002/jps.21415 1:CAS:528:DC%2BD1MXns1SqtQ%3D%3D 18493999
10. PD Graham KJ Brodbeck AJ McHugh 1999 Phase inversion dynamics of PLGA solutions related to drug delivery J Control Release 58 233 245 10.1016/S0168-3659(98)00158-8 1:CAS:528:DyaK1MXhsVentL8%3D 10053196 (Pubitemid 29112894)
11. L Wang S Venkatraman L Kleiner 2004 Drug release from injectable depots: two different in vitro mechanisms J Control Release 99 207 216 10.1016/j.jconrel.2004.06.021 1:CAS:528:DC%2BD2cXns1Chtb4%3D 15380631 (Pubitemid 39222107)
12. R Astaneh M Erfan J Barzin H Mobedi H Moghimi 2008 Effects of ethyl benzoate on performance, morphology and erosion of PLGA implants formed in situ Adv Polym Technol 27 17 26 10.1002/adv.20114 1:CAS:528:DC%2BD1cXhsFaiu73K
13. KJ Brodbeck S Pushpala AJ McHugh 1999 Sustained release of human growth hormone from PLGA solution depots Pharm Res 16 1825 1829 10.1023/A:1018943107688 1:CAS:528:DC%2BD3cXkt1egtw%3D%3D 10644069
14. D Drabkin 1949 The standardization of hemoglobin measurement Am J Med Sci 217 710 711 1:CAS:528:DyaH1MXjsVCntg%3D%3D
15. Iwata M, Tanaka T, Nakamura Y, McGinity JW. Selection of the solvent system for the preparation of poly(D,L-lactic-co-glycolic acid) microspheres containing tumor necrosis factor-alpha (TNF-α). Int J Pharm. 1998;160:145-56.
16. Kranz H, Brazeau GA, Napaporn J, Martin RL, Millard W, Bodmeier R. Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems. Int J Pharm. 2001;212:11-8.
17. Rungseevijitprapa W, Bodmeier R. Injectability of biodegradable in situ forming microparticle systems (ISM). J Pharm Sci. 2009;36:524-31.
18. S Nema RJ Washkuhn RJ Brendel 1997 Excipients and their use in injectable products PDA J Pharm Sci Technol 51 166 171 1:CAS:528:DyaK2sXlvVaqsbs%3D 9277127
19. SL Nielsen 1972 Adipose tissue blood flow determined by the washout of locally injected 133Xenon Scand J Clin Lab Invest 29 31 36 10.3109/ 00365517209081052 1:STN:280:DyaE387ksVOhsw%3D%3D 5014995
20. U.S.Food and Drug Administration. Inactive Ingredient Search for Approved Drug Products. ( http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm ).
21. K Toraishi Y Yuizono N Nakamura S Kato T Aoki K Ashida, et al. 2005 Force requirements and insulin delivery profiles of four injection devices Diabetes Technol Ther 7 629 636 10.1089/dia.2005.7.629 1:CAS:528:DC%2BD2MXovVOiu78%3D 16120038 (Pubitemid 41208627)
22. KJ Brodbeck JR DesNoyer AJ McHugh 1999 Phase inversion dynamics of PLGA solutions related to drug delivery: Part II. The role of solution thermodynamics and bath-side mass transfer J Control Release 62 333 344 10.1016/S0168-3659(99) 00159-5 1:CAS:528:DyaK1MXmvVartr8%3D (Pubitemid 29476581)